Lhasa Limited continues to support the global challenge of nitrosamine impurity assessment

With 164 new nitrite results, bringing the total number to 440 nitrite results for 64 common excipients, Lhasa Limited is pleased to announce the release of the 2021.1 Nitrites in Excipients database.

05 March 2021

Lhasa Limited releases new data to its Nitrites in Excipients project users

15 December 2020

Lhasa Limited releases new data to its Aromatic Amines project users

26 November 2020

Working together to address the potential presence of nitrosamine impurities in medications

Lhasa Limited, in collaboration with Leadscope, Inc., are leading a working group of pharmaceutical toxicologists and consultants investigating the carcinogenic potency and structure-activity relationships of N-nitrosamines.

25 January 2021

Lhasa Limited supports the global challenge of nitrosamine impurity assessment

13 July 2020

The Importance of Pre-competitive Collaborations

26 June 2020

Lhasa Limited continues to support the global challenge of nitrosamine impurity assessment

With 164 new nitrite results, bringing the total number to 440 nitrite results for 64 common excipients, Lhasa Limited is pleased to announce the release of the 2021.1 Nitrites in Excipients database.

05 March 2021

How to better anticipate and mitigate adverse drug reactions [an infographic]

Are you interested in using your data to anticipate and mitigate adverse drug reactions? The Effiris consortium - currently composed of Takeda, GSK and UCB - is working to achieve just that.

17 February 2021

Lhasa Limited continues to support the global challenge of nitrosamine impurity assessment

With 164 new nitrite results, bringing the total number to 440 nitrite results for 64 common excipients, Lhasa Limited is pleased to announce the release of the 2021.1 Nitrites in Excipients database.

05 March 2021

Lhasa Limited releases new data to its Nitrites in Excipients project users

15 December 2020

Lhasa Limited releases new data to its Aromatic Amines project users

26 November 2020

How to better anticipate and mitigate adverse drug reactions [an infographic]

Are you interested in using your data to anticipate and mitigate adverse drug reactions? The Effiris consortium - currently composed of Takeda, GSK and UCB - is working to achieve just that.

17 February 2021

Working together to address the potential presence of nitrosamine impurities in medications

25 January 2021

How Human Resources can positively influence a changing work environment.

18 January 2021